TMCnet News

Advanced Cooling Therapy Adds McArthur Medical Sales as Canadian Distributor for Firm's Esophageal Cooling Device
[November 19, 2014]

Advanced Cooling Therapy Adds McArthur Medical Sales as Canadian Distributor for Firm's Esophageal Cooling Device


CHICAGO --(Business Wire)--

Chicago-based emerging medical device firm Advanced Cooling Therapy (ACT) has named McArthur Medical Sales Inc., headquartered in Ontario, Canada, as the Canadian sales distributor for the firm's first product, the Esophageal Cooling Device (ECD).

Established in 1984, McArthur Medical represents manufacturers from Canada, United States, England and Europe. Through four business units, focusing on Hospital Specialty Products, Medical Supply Dealers, Home Health Care and Retal Pharmacies, the company offers innovative, cost effective and high quality products, prompt service and informed advice.



"Adding McArthur Medical Sales Inc. to our distributor network significantly strengthens our sales presence in Canada. They have an extensive knowledge base in the acute care market and an established reputation in this industry," commented ACT's President and Co-Founder, Erik Kulstad, MD, MS.

The ECD is designed to modulate and control patient temperature when clinically indicated through a single use, fully-enclosed triple lumen system that is inserted into the esophagus. Two lumens attach to existing temperature modulation equipment while a third lumen simultaneously allows gastric decompression and drainage. The ECD can be rapidly inserted by most trained health care professionals, in similar fashion to a standard gastric tube, and can be used to control patient temperature in the operating room, recovery room, emergency room, or ICU. No other product on the market is approved to use the esophageal environment for whole-body temperature modulation. The device has a CE mark for commercial sale in Europe and is licensed for sale in Canada as well. The ECD is pending clearance from the FDA for use in the US.


Advanced Cooling Therapy's novel technology platform provides improved methods to control patient temperature where clinically indicated using the esophageal environment.


[ Back To TMCnet.com's Homepage ]